In GBM, altered expression of EGFR membrane trafficking regulators, resulting in aberrant EGFR localisation, has been associated with tumour progression and therapy resistance to EGFR-targeted therapies [7,8,9,10,11]. The gene discussed is EGFR; the disease is glioblastoma.